Open Label, Multi-Center, Phase 2 Study of KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Previously Treated With First-Line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 20 May 2016
At a glance
- Drugs KOS 1584 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 May 2009 Actual number of patients (1) and trial sponsor (Bristol-Myers Squibb) added as reported by ClinicalTrials.gov.
- 01 May 2009 Actual end date (1 Oct 2008) added as reported by ClinicalTrials.gov
- 01 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.